Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09).
Kawabata R, Izawa N, Suzuki T, Nagahisa Y, Nishikawa K, Takahashi M, Nakamura M, Ishiguro A, Katsuya H, Hihara J, Manaka D, Negoro Y, Tsuji A, Takahashi T, Kochi M, Azuma M, Kadowaki S, Michimae H, Sunakawa Y, Ichikawa W, Fujii M. Kawabata R, et al. Among authors: negoro y. Target Oncol. 2023 May;18(3):359-368. doi: 10.1007/s11523-023-00961-x. Epub 2023 Apr 15. Target Oncol. 2023. PMID: 37060430 Clinical Trial.
Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan.
Aoki M, Kadowaki S, Takahashi N, Suzuki T, Oshima K, Ando T, Yamamoto Y, Kawakami K, Kito Y, Matsumoto T, Shimozaki K, Miyazaki Y, Yamaguchi T, Nagase M, Tamura T, Amanuma Y, Esaki T, Miura Y, Akiyoshi K, Baba E, Makiyama A, Negoro Y, Nakashima K, Sugimoto N, Nagashima K, Shoji H, Boku N. Aoki M, et al. Among authors: negoro y. Gastric Cancer. 2023 Jan;26(1):132-144. doi: 10.1007/s10120-022-01349-y. Epub 2022 Nov 1. Gastric Cancer. 2023. PMID: 36316527 Free PMC article.
Acute adverse events of ultra-hypofractionated whole-breast irradiation after breast-conserving surgery for early breast cancer in Japan: an interim analysis of the multi-institutional phase II UPBEAT study.
Tokuda PJK, Mitsuyoshi T, Ono Y, Kishi T, Negoro Y, Okumura S, Ikeda I, Sakamoto T, Kokubo Y, Ashida R, Imagumbai T, Yamashita M, Tanabe H, Takebe S, Tokiwa M, Suzuki E, Yamauchi C, Yoshimura M, Mizowaki T, Kokubo M; Kyoto Radiation Oncology Study Group. Tokuda PJK, et al. Among authors: negoro y. Breast Cancer. 2024 Apr 12. doi: 10.1007/s12282-024-01577-3. Online ahead of print. Breast Cancer. 2024. PMID: 38607499
Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study.
Dote S, Shiwaku E, Kohno E, Fujii R, Mashimo K, Morimoto N, Yoshino M, Odaira N, Ikesue H, Hirabatake M, Takahashi K, Takahashi M, Takagi M, Nishiuma S, Ito K, Shimato A, Itakura S, Takahashi Y, Negoro Y, Shigemori M, Watanabe H, Hayasaka D, Nakao M, Tasaka M, Goto E, Kataoka N, Yokomizo A, Kobayashi A, Nakata Y, Miyake M, Hayashi Y, Yamamoto Y, Hirata T, Azuma K, Makihara K, Fukui R, Tokutome A, Yagisawa K, Honda S, Meguro Y, Suzuki S, Yamaguchi D, Miyata H, Kobayashi Y; IMBERA Investigators. Dote S, et al. Among authors: negoro y. Int J Clin Oncol. 2023 Aug;28(8):1054-1062. doi: 10.1007/s10147-023-02357-3. Epub 2023 Jun 1. Int J Clin Oncol. 2023. PMID: 37261583 Free PMC article.
Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer.
Yamaguchi K, Minashi K, Sakai D, Nishina T, Omuro Y, Tsuda M, Iwagami S, Kawakami H, Esaki T, Sugimoto N, Oshima T, Kato K, Amagai K, Hosaka H, Komine K, Yasui H, Negoro Y, Ishido K, Tsushima T, Han S, Shiratori S, Takami T, Shitara K. Yamaguchi K, et al. Among authors: negoro y. Cancer Sci. 2022 Aug;113(8):2814-2827. doi: 10.1111/cas.15462. Epub 2022 Jul 1. Cancer Sci. 2022. PMID: 35701865 Free PMC article. Clinical Trial.
Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years.
Moriwaki T, Nishina T, Sakai Y, Yamamoto Y, Shimada M, Ishida H, Amagai K, Sato M, Endo S, Negoro Y, Kuramochi H, Denda T, Hatachi Y, Ikezawa K, Nakajima G, Bando Y, Tsuji A, Yamamoto Y, Morimoto M, Kobayashi K, Hyodo I. Moriwaki T, et al. Among authors: negoro y. Jpn J Clin Oncol. 2022 Jul 8;52(7):725-734. doi: 10.1093/jjco/hyac073. Jpn J Clin Oncol. 2022. PMID: 35470391 Clinical Trial.
Long-term outcomes of an esophagus-preserving chemoradiotherapy strategy for patients with endoscopically unresectable stage I thoracic esophageal squamous cell carcinoma.
Suwa T, Ishida Y, Negoro Y, Kusumi F, Kadokawa Y, Aizawa R, Nakajima T, Okamoto Y, Okuno Y, Yamada K, Ogura M, Murakami M, Mizowaki T. Suwa T, et al. Among authors: negoro y. Clin Transl Radiat Oncol. 2021 Aug 11;30:88-94. doi: 10.1016/j.ctro.2021.08.002. eCollection 2021 Sep. Clin Transl Radiat Oncol. 2021. PMID: 34430719 Free PMC article.
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment.
Nakajima H, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Negoro Y, Komoda M, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Ando K, Yuki S, Okuyama H, Kusaba H, Sakai D, Okamoto K, Tamura T, Yamashita K, Gosho M, Moriwaki T. Nakajima H, et al. Among authors: negoro y. Front Oncol. 2021 Jun 15;11:688709. doi: 10.3389/fonc.2021.688709. eCollection 2021. Front Oncol. 2021. PMID: 34211856 Free PMC article.
92 results